Business
Gilead Sciences to Acquire Arcellx in $8 Billion Deal to Bolster Cell Therapy Pipeline
Gilead Sciences has announced a definitive agreement to acquire Arcellx for nearly $8 billion, a move designed to cement its leadership in the competitive oncology market. The acquisition focuses on advancing next-generation CAR-T therapies for patients with multiple myeloma.
February 24, 2026734 views
Score0
Enjoyed this story? Share it! 👇
Advertisement
Related Stories
Business
Wellness Franchises Drive 2026 Economic Growth as Membership Models Replace Fast Food Dominance
1d ago
Business
Morgan Wallen Secures Twentieth No. 1 with '20 Cigarettes' as Country Airplay Milestone Reshapes History
1d ago
Business
Michael Burry Issues 'Catastrophic' Risk Warning Over Nvidia Market Position
1d ago
Business
The Quarter-Salary Sacrifice: New Study Reveals the Steep Price Workers Pay for Remote Freedom
1d ago
Comments (0)
Sign in to leave a comment.
No comments yet. Be the first to share your thoughts!